 15. concomitant oral or i.v. therapy with strong CYP3A Inhibitors e.g. ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice 1 Ld, CYP3A substrates with narrow therapeutic indices e.g. cyclosporine, quinidine, or strong CYP3A inducers e.g. rifampinrifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital that cannot be safely discontinued 